Janux Therapeutics, Inc. - COMMON STOCK (JANX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
JANX on Nasdaq
Shares outstanding
60,558,345
Price per share
$13.80
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
65,054,632
Total reported value
$1,589,759,767
% of total 13F portfolios
0%
Share change
-290,409
Value change
-$4,062,568
Number of holders
168
Price from insider filings
$13.80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Janux Therapeutics, Inc. - COMMON STOCK (JANX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% $383,922,060 11,971,377 RA Capital Management, L.P. 06 Mar 2025
JANUS HENDERSON GROUP PLC 10% +31% $147,469,714 +$38,459,199 6,033,949 +35% JANUS HENDERSON GROUP PLC 31 Oct 2025
FMR LLC 5.8% $48,484,949 3,512,384 FMR LLC 31 Dec 2025
BlackRock, Inc. 5.7% $77,284,838 3,345,664 BlackRock, Inc. 30 Jun 2025
Paradigm Biocapital Advisors LP 4.9% -18% $73,444,489 -$14,982,559 2,920,258 -17% Paradigm BioCapital Advisors LP 30 Jun 2025
Adage Capital Management, L.P. 4.3% -21% $63,503,750 -$13,499,262 2,525,000 -18% Adage Capital Management, L.P. 30 Jun 2025

As of 30 Sep 2025, 168 institutional investors reported holding 65,054,632 shares of Janux Therapeutics, Inc. - COMMON STOCK (JANX). This represents 107% of the company’s total 60,558,345 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 18% 11,189,693 0% 3.4% $273,476,097
FMR LLC 15% 9,056,062 +1.9% 0.01% $221,330,155
JANUS HENDERSON GROUP PLC 7.8% 4,701,112 +5.4% 0.05% $114,988,241
BlackRock, Inc. 6.2% 3,730,994 +9.6% 0% $91,185,492
Paradigm Biocapital Advisors LP 4.8% 2,920,258 0% 2.1% $71,371,106
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.6% 2,775,000 +9.9% 0.11% $67,821,000
VANGUARD GROUP INC 4% 2,417,104 +10% 0% $59,074,022
STATE STREET CORP 3.1% 1,891,465 +36% 0% $46,227,405
ORBIMED ADVISORS LLC 2.9% 1,766,100 +46% 1% $43,163,484
Point72 Asset Management, L.P. 2.8% 1,710,200 -20% 0.09% $41,797,288
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 1,265,556 -29% 0% $30,931,000
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,083,864 +20% 0% $26,494,551
Woodline Partners LP 1.7% 1,026,938 -17% 0.12% $25,098,365
T. Rowe Price Investment Management, Inc. 1.6% 972,691 0.01% $23,773,000
READYSTATE ASSET MANAGEMENT LP 1.6% 960,379 +38% 1.1% $23,471,663
Logos Global Management LP 1.5% 935,000 -6.5% 2.3% $22,851,400
FRANKLIN RESOURCES INC 1.5% 887,755 -17% 0.01% $21,696,730
Prosight Management, LP 1.4% 865,350 +1.3% 5.1% $21,149,154
Cormorant Asset Management, LP 1.4% 850,000 -43% 1.4% $20,774,000
CITADEL ADVISORS LLC 1.3% 802,784 -35% 0.02% $19,620,041
WELLINGTON MANAGEMENT GROUP LLP 1.2% 701,604 +42% 0% $17,147,203
TANG CAPITAL MANAGEMENT LLC 1.2% 700,000 +250% 0.66% $17,108,000
GOLDMAN SACHS GROUP INC 1.1% 655,108 +88% 0% $16,010,840
First Turn Management, LLC 1.1% 639,699 +43% 2.3% $15,634,244
MPM BIOIMPACT LLC 1% 614,282 0% 2.5% $15,013,052

Institutional Holders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 137,263 $1,893,755 +$650,187 $13.80 4
2025 Q3 65,054,632 $1,589,759,767 -$4,062,568 $24.44 168
2025 Q2 65,389,958 $1,510,522,459 -$28,053,981 $23.10 169
2025 Q1 66,482,175 $1,805,570,973 -$17,647,630 $27.00 179
2024 Q4 64,089,510 $3,430,809,553 +$1,001,839,547 $53.54 213
2024 Q3 45,621,730 $2,072,353,785 +$42,332,014 $45.43 158
2024 Q2 44,723,442 $1,873,142,325 +$107,659,314 $41.89 153
2024 Q1 42,327,541 $1,593,608,078 +$334,250,630 $37.65 118
2023 Q4 33,501,695 $359,539,970 -$17,204,195 $10.73 64
2023 Q3 35,112,124 $353,984,587 +$45,518,472 $10.08 57
2023 Q2 30,508,831 $362,117,070 -$408,523 $11.87 54
2023 Q1 30,541,873 $369,527,936 +$18,629,245 $12.10 48
2022 Q4 28,954,042 $381,308,644 -$7,758,264 $13.17 49
2022 Q3 29,548,436 $400,093,845 +$8,918,649 $13.54 45
2022 Q2 28,911,820 $352,963,471 +$6,297,905 $12.21 43
2022 Q1 28,388,419 $407,113,023 +$11,406,319 $14.34 46
2021 Q4 27,496,946 $541,627,745 +$19,103,067 $19.73 46
2021 Q3 26,499,088 $571,208,440 +$35,499,490 $21.63 44
2021 Q2 24,743,225 $614,460,000 +$614,460,000 $24.95 29